A Meta-Analysis on the Effectiveness and Safety of FOLFOX Plus Bevacizumab for Colorectal Cancer Treatment - Takeaways - MDSpire

A Meta-Analysis on the Effectiveness and Safety of FOLFOX Plus Bevacizumab for Colorectal Cancer Treatment

Share

1

This meta-analysis evaluates the safety and efficacy of bevacizumab combined with FOLFOX for colorectal cancer treatment.
2

Eleven randomized controlled trials were included, comparing FOLFOX plus bevacizumab with FOLFOX alone.
3

The combination significantly improved overall response rate (ORR) and disease control rate (DCR) compared to FOLFOX alone.
4

No significant differences were found in gastrointestinal reactions, leukopenia, liver injury, neurotoxicity, or hypertension.
5

Evidence for long-term survival benefits and quality-of-life improvements with this combination therapy remains insufficient.